In particular, repeated intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care for nAMD, DME with center-involving macular edema, and RVO-associated macular edema [6]. The gene discussed is VEGFA; the disease is macular retinal edema.